Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
2
×
boston blog main
boston top stories
life sciences
2
×
national blog main
national top stories
san francisco blog main
san francisco top stories
alex azar
alliance for aging research
biogen
biotech
biotechnology innovation organization
boulder/denver blog main
boulder/denver top stories
cancer
cancer drugs
clinical trials
cobimetinib
deals
detroit blog main
detroit top stories
drug pricing
duane schulthess
eli lilly
erica whittaker
fda
indiana blog main
indiana top stories
investing
ipo
jim greenwood
medicaid
medicare
nancy pelosi
natalizumab
national
new york blog main
new york top stories
raleigh-durham blog main
What
despite
2
×
drug
administration
angry
anti
benefited
cancer
family
fear
hardest
hit
hottest
hunters
industry
ipo
losing
medicines
pharma
plans
presidential
price
proteins
ras
reels
research
revolution
rhetoric
rx
scalps
split
targets
thanks
trump
tweets
Language
unset
Current search:
despite
×
amgen
×
" life sciences "
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans